BD Boston Conference Hosted by BD Heads of Shire, Merck, Sanofi, Roche, Biogen, Teva, Nestle, AbbVie on March 9th

Share Article

Join Iain Dukes (SVP, Merck), H. Martin Seidel (Global Head, Novartis), Paul Biondi (SVP, Bristol-Myers Squibb), Detlev Biniszkiewicz (CEO, Surface Oncology), Gustav Christensen (CEO, Dyax), Henry Gosebruch (EVP, AbbVie), Martin Hendrix (Head, M&A, Nestle Health Science), Blaine McKee (SVP, Shire), Ivana Magovcevic-Liebisch (SVP, Teva), Chris Viehbacher (Managing Partner, Gurnet Point Capital), Christoph Westphal (Co-Founder, Longwood Fund) in Boston for an off-the-record forum on partnerships, deal-making and business development in biopharma in a high energy networking event at the end of the Cowen Healthcare Conference.

BD Boston brings together an experienced group of professionals with great perspective and insight into today's volatile markets

Life science decision makers, entrepreneurs, venture capitalists, buysiders, corporate venture and investors will gather at the 2016 BD Boston Conference on March 9th at The Westin Copley Place, 10 Huntington Avenue, Boston, MA.

The BD Conference is an off-the-record forum for leading executives in the life sciences, offering exclusive access to key decision makers who influence deal making and investment. Attendees gain insights from presentations and panels featuring business development leaders from several of the world’s leading biopharmaceutical companies. Healthcare and finance investors also attend this world class meeting.

Panel topics include the biotech incubators; from start up to public; growth options; forging innovative partnerships; building a robust pipeline; when to think commercial; takeovers; placing the patient at the center of the business model; the future of deal-making; managing shareholder expectations; which sectors are hot and more. "BD Boston brings together an experienced group of professionals with great perspective and insight into today's volatile markets," says James Cappuccio, Managing Director, Investment Banking at H.C. Wainwright & Co. “The conference format provides unique access to the most influential money managers, executives and advisors in biotechnology. We expect this year’s conference to be extraordinarily valuable given the challenging start to 2016 and the upcoming Presidential election.”

The BD Boston Deal of the Year Award will be presented Wednesday, March 9 at 5:00 pm.

Additional conference speakers include Christopher Burnley (CBO, FORUM Pharmaceuticals), Mary Lynne Hedley (COO, Tesaro), Philippe Lopes-Fernandes (SVP, EMD Serono), Mathai Mammen (SVP, Theravance BioPharma), Roger Pomerantz (CEO, Seres Therapeutics), Adrian Rawcliffe (CFO, AdaptImmune), Steve Tregay (CEO, Forma Therapeutics), Robert Urban (Head, Johnson & Johnson Innovation, Boston), and many more prominent industry leaders.

BD Boston is sponsored by Alexandria, L.E.K. Consulting, H.C. Wainwright & Co. and BioPharma Executive Council.

For more information or to register for the conference, visit:


The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of biopharma leaders, which will help to drive innovation in biotech by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information sharing, networking and corporate development within the biopharma community. These off-the-record forums bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information or to register, visit:

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Arielle Jackson
Follow >
Boston Biotech Conferences
since: 05/2012
Like >
Visit website